CN115770249A - 治疗大肠癌的药物组合物及其用途 - Google Patents
治疗大肠癌的药物组合物及其用途 Download PDFInfo
- Publication number
- CN115770249A CN115770249A CN202111039458.4A CN202111039458A CN115770249A CN 115770249 A CN115770249 A CN 115770249A CN 202111039458 A CN202111039458 A CN 202111039458A CN 115770249 A CN115770249 A CN 115770249A
- Authority
- CN
- China
- Prior art keywords
- emodin
- solasodine
- pharmaceutical composition
- colorectal cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 37
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims abstract description 75
- KWVISVAMQJWJSZ-VKROHFNGSA-N solasodine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 KWVISVAMQJWJSZ-VKROHFNGSA-N 0.000 claims abstract description 74
- JXWLYDNHVXFBJA-UHFFFAOYSA-N solasodine Natural products CC1CCC2(NC1)NC3CC4C5CC=C6CC(O)CCC6(C)C5CCC4(C)C3C2C JXWLYDNHVXFBJA-UHFFFAOYSA-N 0.000 claims abstract description 65
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000010282 Emodin Substances 0.000 claims abstract description 60
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims abstract description 60
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims abstract description 60
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims abstract description 60
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims abstract description 60
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 238000002347 injection Methods 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 201000010989 colorectal carcinoma Diseases 0.000 abstract description 13
- 230000033115 angiogenesis Effects 0.000 abstract description 10
- 230000006907 apoptotic process Effects 0.000 abstract description 9
- 206010027476 Metastases Diseases 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 7
- 230000009401 metastasis Effects 0.000 abstract description 7
- 238000002626 targeted therapy Methods 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 230000004614 tumor growth Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 16
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 16
- 239000012528 membrane Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002033 PVDF binder Substances 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000011729 BALB/c nude mouse Methods 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 201000011061 large intestine cancer Diseases 0.000 description 7
- 238000009835 boiling Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 5
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 102100029855 Caspase-3 Human genes 0.000 description 4
- 102000004091 Caspase-8 Human genes 0.000 description 4
- 108090000538 Caspase-8 Proteins 0.000 description 4
- 102000004039 Caspase-9 Human genes 0.000 description 4
- 108090000566 Caspase-9 Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000219066 Actinidiaceae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- 240000001745 Rheum palmatum Species 0.000 description 2
- 235000008090 Rheum palmatum Nutrition 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 241000208292 Solanaceae Species 0.000 description 2
- 244000061457 Solanum nigrum Species 0.000 description 2
- 235000002594 Solanum nigrum Nutrition 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 244000298800 Actinidia arguta Species 0.000 description 1
- 235000016416 Actinidia arguta Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- PQUOYNVEQWXFHJ-UHFFFAOYSA-N Solanidin Natural products CC1CCC2C(C)C3(C)C4CCC5C(CC=C6CC(O)CCC56C)C4CC3N2C1 PQUOYNVEQWXFHJ-UHFFFAOYSA-N 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- LFYFMIISECOQEE-UHFFFAOYSA-N Solasodin Natural products N1CC(C)CCC11OC(CC2C3(CCC4C5(C)CCC(O)CC5=CCC42)C)C3C1 LFYFMIISECOQEE-UHFFFAOYSA-N 0.000 description 1
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 1
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 solancapidine Chemical compound 0.000 description 1
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 description 1
- 229940031352 solanine Drugs 0.000 description 1
- 229930003352 steroid alkaloid Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗大肠癌的药物组合物,其组分及其重量百分比分别为澳洲茄胺5‑95%、大黄素5‑95%。该药物组合物用于治疗大肠癌治疗可以抑制细胞增殖和肿瘤生长,诱导细胞凋亡,抑制血管生成和转移的作用,并可协同手术、放化疗、靶向治疗及生物与免疫治疗用于大肠癌的治疗。本发明药物组合物可以是颗粒剂、胶囊、片剂、丸剂、口服液、注射液或汤剂等剂型。
Description
技术领域
本发明涉及一种治疗大肠癌的药物组合物。
背景技术
大肠癌是常见恶性肿瘤,晚期可见淋巴结、肝、肺、骨等部位转移。
根据病情的不同,大肠癌可以采用手术、放化疗以及靶向治疗等治疗,但远期疗效有待进一步提高。中医药是我国重要的生物医药资源,在大肠癌的治疗中发挥了重要的作用,但比较缺乏组方合理、疗效肯定的中药组方(组合);研发可以治疗大肠癌的中药组方具有重要的意义。
本发明人经多年研究,结合中医肿瘤基础与临床进展,科学配伍抗癌中药资源,发明了一种治疗大肠癌的药物组合物;该药物组合物具有解毒、散结、抗癌的功效,用于治疗大肠癌治疗可以抑制细胞增殖和肿瘤生长,诱导细胞凋亡,抑制血管生成和转移的作用,并可协同手术、放化疗、靶向治疗及生物与免疫治疗用于大肠癌的治疗。
发明内容
针对现有技术的上述不足,根据本发明的实施例,希望提供一种治疗大肠癌的药物组合物,该药物组合物对大肠癌具有多重作用,可以联合手术、化疗、放疗和靶向治疗等现代治疗大肠癌,也可以单独用于大肠癌的治疗。
根据实施例,本发明提供的一种治疗大肠癌的药物组合物,其组分及其重量百分比分别为澳洲茄胺5-95%、大黄素5-95%,优选地,澳洲茄胺10-90%、大黄素10-90%。
根据一个实施例,本发明前述治疗大肠癌的药物组合物,可与药学上可接受的载体或辅料混合,制备成制剂,所述制剂优选颗粒剂、片剂、胶囊剂、丸剂、口服液或注射液。
本发明前述治疗大肠癌的药物组合物中,澳洲茄胺(Solasodine,Purapuridine,Solancarpidine,Solasodin,SLSD)分子式:C27H43NO2,CAS号;126-17-0,是一种类固醇生物碱,存在于多种茄科植物中,如龙葵(茄科茄属植物龙葵Solanum nigrum L.)。
大黄素(Emodin,Frangula emodin,EMD)分子式:C15H10O5,CAS号:518-82-1,是一种蒽醌衍生物;存在于多种中药,如藤梨根(猕猴桃科植物猕猴桃根Actinidia chinensisPlanch.,或猕猴桃科植物软枣猕猴桃根Actinidia arguta(Zucc.)Planch.ex Miq.),大黄(蓼科植物掌叶大黄Rheum palmatum L.,唐古特大黄Rheum tanguticum Maxim. ex Balf,或药用大黄Rheum officinale Baill)。
本发明前述治疗大肠癌的药物组合物,其制备方法并无特别之处,按重量百分比分别称取澳洲茄胺和大黄素,混合均匀,与药学上可接受的载体或辅料混合,制备成颗粒剂、片剂、胶囊剂、丸剂、口服液或注射液。
随后的实施例和试验例将证明,本发明药物组合物用于大肠癌的治疗可以抑制细胞增殖和肿瘤生长,诱导细胞凋亡,抑制血管生成和转移的作用,并可协同手术、放化疗、靶向治疗及生物与免疫治疗用于大肠癌的治疗。
附图说明
图1澳洲茄胺和大黄素对大肠癌HCT116细胞增殖作用效果图(A为澳洲茄胺对HCT116 细胞增殖的作用,B为大黄素对HCT116细胞增殖的作用,C为澳洲茄胺联合大黄素对HCT116 细胞增殖的作用)。
图2澳洲茄胺和大黄素对大肠癌HCT116细胞凋亡作用效果图(A为流式细胞仪检测, B为细胞凋亡分析)。
图3澳洲茄胺和大黄素对大肠癌HCT116细胞Caspases作用效果图(A为Caspase-3,B为Caspase-8,C为Caspase-9)。
图4澳洲茄胺和大黄素对大肠癌HCT116肿瘤生长作用效果图(A为肿瘤体积,B为肿瘤质量)。
图5澳洲茄胺和大黄素对CT26大肠癌转移作用效果图(A为转移结节,B为肺质量)。
图6澳洲茄胺和大黄素对CT26大肠癌LOX表达作用效果图(A为Western blot检测,B为免疫组织化学染色检测,C为蛋白表达分析)。
图7澳洲茄胺和大黄素对CT26大肠癌FAK和Src表达与磷酸化作用效果图(A为Western blot检测,B为蛋白表达与磷酸化分析)。
图8澳洲茄胺和大黄素对CT26大肠癌HIF-1α和VEGFA表达作用效果图(A为Westernblot检测,B为蛋白表达分析)。
图9澳洲茄胺和大黄素对CT26大肠癌血管生成作用效果图(A为免疫组织化学染色检测,B为血管生成分析)。
具体实施方式
下面结合附图和具体实施例,进一步阐述本发明。这些实施例应理解为仅用于说明本发明而不用于限制本发明的保护范围。在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等效变化和修改同样落入本发明权利要求所限定的范围。
本发明以下实施例和试验例中,澳洲茄胺和大黄素均为市售纯度98%的标准品。
试验例1(澳洲茄胺和大黄素对大肠癌HCT116细胞增殖作用)
将5×103大肠癌HCT-116细胞分别接种于96孔板内,等待细胞完全贴壁(24h)后分别加入澳洲茄胺(8-48μM)或大黄素(10-320μM),对照组加入等体积DMSO,每组3 个复孔;作用48h后,加入10μl CCK-8试剂,培养箱中孵育2h,酶标仪(450nm)检测OD值,依照公式计算细胞存活率:细胞存活率(%)=(实验组OD/对照组OD)×100 (图1A和B)。
联合用药试验例中分别加入澳洲茄胺(20μM)或/和大黄素(80μM)或等体积DMSO,作用24-96小时,加入10μl CCK-8试剂,培养箱中孵育2h,酶标仪(450nm)检测OD 值,依照公式计算细胞存活率:细胞存活率(%)=(实验组OD/对照组OD)×100(图1C)。
实验结果如图1所示,澳洲茄胺和大黄素可抑制HCT116细胞增殖,两药联合可协同抑制HCT116细胞增殖。
试验例2(澳洲茄胺和大黄素对大肠癌HCT116细胞凋亡作用)
2.5×105HCT-116细胞接种于6孔板中,培养箱孵育24h贴壁后,每组3个复孔,分别加入澳洲茄胺(20μM)或/和大黄素(80μM)或等体积DMSO。培养箱孵育48h后收集培养基及细胞,PBS离心洗涤一次,使用稀释后结合缓冲液150μl重悬细胞。避光条件下,每样本5μlAnnexinV-FITC标记15min,加1ml结合缓冲液1400rpm离心4min,去上清液,加150ul缓冲液重悬,继与5μl PI孵育5min,后加150μl缓冲液重悬细胞,流式细胞仪检测细胞凋亡。
实验结果如图3所示,澳洲茄胺和大黄素可诱导HCT116细胞凋亡,两药联合可增强对HCT116细胞凋亡的作用。
试验例3(澳洲茄胺和大黄素对大肠癌HCT116细胞Caspases作用)
以Ac-DEVD-pNA、Ac-IETD-pNA、Ac-LEHD-pNA为底物,检测澳洲茄胺和/或大黄素作用后HCT-116细胞Caspase-3、8和9活性。2.5×105HCT-116细胞接种于6孔板中,培养箱孵育24h贴壁后,每组3个复孔,分别加入澳洲茄胺(20μM)或/和大黄素(80μM) 或等体积DMSO作用48h,收集HCT-116细胞,加入裂解液冰浴15min,4℃离心机,19000rpm 离心15min,Bradford法测定蛋白浓度;依次加入测定缓冲液、样品、底物,分别为40 μl,50μl,10μl,轻轻混匀(注意避免出现气泡),37℃孵育2h后,酶标仪检测405nm OD值,结合蛋白浓度计算Caspases活性。
实验结果如图3所示,澳洲茄胺和大黄素可活化Caspase-3、8和9,两药联合可增强对Caspase-3、8和9活性的作用。
试验例4(澳洲茄胺和大黄素对大肠癌HCT116肿瘤生长作用)
常规培养HCT-1160细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,肿瘤生长至可触及后,将裸小鼠随机分为:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;每三天测量小鼠体重及肿瘤大小;治疗21天后处死小鼠,取裸鼠肿瘤,称重。肿瘤体积(mm3)=π/6 ×长径×短径2。
实验结果如图4所示,澳洲茄胺和大黄素可抑制大肠癌肿瘤生长,两药联合可增强对肿瘤生长的抑制作用。
试验例5(澳洲茄胺和大黄素对CT26大肠癌转移作用)
常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺 +大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/ 和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺称重、计数肺表面转移结节,-80℃保存肺组织备用。
实验结果如图5所示,澳洲茄胺和大黄素可抑制大肠癌转移,两药联合可增强对大肠癌转移的抑制作用。
试验例6(澳洲茄胺和大黄素对CT26大肠癌LOX表达作用)
Western blot检测蛋白表达。常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺,RIPA裂解液裂解蛋白,BCA试剂盒定量,蛋白在100℃沸水中煮沸5min变性,在10%的凝胶中电泳;半干法转印蛋白至PVDF膜,200mA恒流转膜60min,放入5%脱脂奶粉室温封闭2h,与LOX抗体4℃孵育过夜,TBST洗膜,洗3次每次5min,辣根过氧化物酶标记的二抗室温孵育2h,TBST洗膜,每次5min洗3次,化学发光检测试剂ECL反应2min,保鲜膜包好PVDF膜,暗室中用x胶片感光、显影、定影,分析蛋白表达。
免疫组化法检测蛋白表达。常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺,石蜡包埋肺组织,4μm切片,置于烘箱中60℃1h,柠檬酸钠抗原修复液,煮沸热修复4.3%H2O2孵育15min,血清封闭,LOX抗体4℃孵育过夜,PBS冲洗3次,二抗37℃孵育30min,二氨基联苯胺(Diaminobenzidine,DAB)为底物显色,苏木素复染,盐酸酒精分化,水洗,梯度酒精脱水,树脂封片,显微镜下观察、拍照,用Image Pro 6.0软件分析蛋白表达。
实验结果如图6所示,澳洲茄胺和大黄素可抑制大肠癌LOX表达,两药联合可增强对 LOX表达的抑制作用。
试验例7(澳洲茄胺和大黄素对CT26大肠癌FAK和Src表达与磷酸化作用)
Western blot检测蛋白表达。常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺,RIPA裂解液裂解蛋白,BCA试剂盒定量,蛋白在100℃沸水中煮沸5min变性,蛋白在8-10%的凝胶中电泳;半干法转印蛋白至PVDF膜,200mA恒流转膜60min,放入5%脱脂奶粉室温封闭2h,与特异一抗4℃孵育过夜,TBST洗膜,洗3次每次5min,辣根过氧化物酶标记的二抗室温孵育2h,TBST洗膜,每次5min洗3次,化学发光检测试剂 ECL反应2min,保鲜膜包好PVDF膜,暗室中用x胶片感光、显影、定影,分析蛋白表达和磷酸化。
实验结果如图7所示,澳洲茄胺和大黄素可抑制大肠癌FAK和Src磷酸化,两药联合可增强对FAK和Src磷酸化的抑制作用。
试验例8(澳洲茄胺和大黄素对CT26大肠癌HIF-1α和VEGFA表达作用)
Western blot检测蛋白表达。常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺,RIPA裂解液裂解蛋白,BCA试剂盒定量,蛋白在100℃沸水中煮沸5min变性,蛋白在8-10%的凝胶中电泳;半干法转印蛋白至PVDF膜,200mA恒流转膜60min,放入5%脱脂奶粉室温封闭2h,与HIF-1α或VEGFA抗体4℃孵育过夜,TBST洗膜,洗3次每次5min,辣根过氧化物酶标记的二抗室温孵育2h,TBST洗膜,每次5min洗3次,化学发光检测试剂ECL反应2min,保鲜膜包好PVDF膜,暗室中用x胶片感光、显影、定影。
实验结果如图8所示,澳洲茄胺和大黄素可抑制HIF-1α和VEGFA表达,两药联合可增强对HIF-1α和VEGFA表达的抑制作用。
试验例9(澳洲茄胺和大黄素对CT26大肠癌血管生成作用)
以CD31为标志蛋白,免疫组化检测血管生成。常规培养大肠癌CT26细胞,计数后,调细胞浓度为3×107个/ml,予以每只BALB/c裸小鼠皮下注射0.1ml细胞悬液,随机分组:对照组、澳洲茄胺组、大黄素组、澳洲茄胺+大黄素组,每组10只;分别给予灭菌水(含等体积DMSO)、澳洲茄胺(1mg/0.2ml)或/和大黄素(1mg/0.2ml)治疗,每天灌胃一次;治疗15天后处死小鼠,取肺,石蜡包埋肺组织,4μm切片,置于烘箱中60℃1h,柠檬酸钠抗原修复液,煮沸热修复4.3%H2O2孵育15min,血清封闭,CD31抗体4℃孵育过夜, PBS冲洗3次,二抗37℃孵育30min,DAB显色,苏木素复染,盐酸酒精分化,水洗,梯度酒精脱水,树脂封片,显微镜下观察、拍照,用Image Pro 6.0软件分析血管生成。
实验结果如图9所示,澳洲茄胺和大黄素可抑制抑制大肠癌血管生成,两药联合可增强对大肠癌血管生成的抑制作用。
实施例1(颗粒剂的制备)
称取澳洲茄胺10g、大黄素11g,加入适当辅料,制粒,整粒,成颗粒剂。
实施例2(胶囊剂的制备)
称取澳洲茄胺12g、大黄素10g,加入适当辅料,制粒,整粒,装入胶囊,制成。
实施例3(片剂的制备)
称取澳洲茄胺8g、大黄素15g,加入适当辅料,压片,包衣,即得。
实施例4(丸剂的制备)
称取澳洲茄胺16g、大黄素18g,加入适当辅料,制丸,即得。
实施例5(口服液的制备)
称取澳洲茄胺6g、大黄素9g,加入适当辅料,制成口服液。
实施例6(注射剂的制备)
称取澳洲茄胺8g、大黄素5g,加水溶解,加入适当辅料,粗滤,精滤,灌装,熔封,制成注射剂。
此外,本发明所述的药物组合物还可按常规方法制成汤剂、酒剂、散剂、膏剂等药学上可接受的剂型。
Claims (8)
1.一种治疗大肠癌的药物组合物,其特征在于,其活性组分为澳洲茄胺和大黄素。
2.根据权利要求1所述的治疗大肠癌的药物组合物,其特征在于,活性组分的重量百分比分别为澳洲茄胺5-95%、大黄素5-95%。
3.根据权利要求1所述的治疗大肠癌的药物组合物,其特征在于,活性组分的重量百分比分别为澳洲茄胺10-90%、大黄素10-90%。
4.根据权利要求1所述的治疗大肠癌的药物组合物,其特征在于,活性组分的用量分别为澳洲茄胺8-48μM、大黄素10-320μM。
5.根据权利要求1所述的治疗大肠癌的药物组合物,其特征在于,活性组分的用量分别为澳洲茄胺1mg/0.2ml、大黄素1mg/0.2ml。
6.如权利要求1-5中任何一项所述的治疗大肠癌的药物组合物,其特征在于,其与药学上可接受的载体或辅料混合,制备成制剂。
7.如权利要求6所述的治疗大肠癌的药物组合物,其特征在于,所述制剂为颗粒剂、片剂、胶囊剂、丸剂、口服液或注射液。
8.权利要求1-7中任何一项所述的药物组合物在制备防治大肠癌的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111039458.4A CN115770249A (zh) | 2021-09-06 | 2021-09-06 | 治疗大肠癌的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111039458.4A CN115770249A (zh) | 2021-09-06 | 2021-09-06 | 治疗大肠癌的药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115770249A true CN115770249A (zh) | 2023-03-10 |
Family
ID=85387429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111039458.4A Pending CN115770249A (zh) | 2021-09-06 | 2021-09-06 | 治疗大肠癌的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115770249A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083330A (zh) * | 2011-11-01 | 2013-05-08 | 复旦大学 | 澳洲茄胺在制备抗肿瘤药物中的应用 |
-
2021
- 2021-09-06 CN CN202111039458.4A patent/CN115770249A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083330A (zh) * | 2011-11-01 | 2013-05-08 | 复旦大学 | 澳洲茄胺在制备抗肿瘤药物中的应用 |
Non-Patent Citations (2)
Title |
---|
徐凇;: "中药单体逆转大肠癌多药耐药的研究进展", 中成药, vol. 40, no. 12, pages 2728 - 2731 * |
王菁雯等: "中医药对大肠癌信号通路的调控作用", 中国实验方剂学杂志, vol. 24, no. 01, pages 227 - 234 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway | |
Kim et al. | Natural products for pancreatic cancer treatment: From traditional medicine to modern drug discovery | |
Halicka et al. | Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES | |
Lan et al. | Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway | |
Yan et al. | Banxia Xiexin decoction, a traditional Chinese medicine, alleviates colon cancer in nude mice | |
Tu et al. | Treatment of spleen-deficiency syndrome with Atractyloside A from bran-processed Atractylodes lancea by protection of the intestinal mucosal barrier | |
Sun et al. | Biejiajian pill inhibits carcinogenesis and metastasis via the akt/GSK-3β/snail signaling pathway in hepatocellular carcinoma | |
Xiao et al. | Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT | |
Wen et al. | Astragali Radix Contributes to the Inhibition of Liver Fibrosis via High‐Mobility Group Box 1‐Mediated Inflammatory Signaling Pathway | |
Tan et al. | Erchen Plus Huiyanzhuyu Decoction Inhibits the Growth of Laryngeal Carcinoma in a Mouse Model of Phlegm‐Coagulation‐Blood‐Stasis Syndrome via the STAT3/Cyclin D1 Pathway | |
Nagaraj et al. | MTA1 induced angiogenesis, migration and tumor growth is inhibited by Glycyrrhiza glabra | |
Nurhidayati et al. | Antiangiogenesis Activity of Awar-Awar Leaf Extract (Ficus Septica Burm. F.) In Chorioallantoic Membrane Assay. | |
CN112552155A (zh) | 一种高良姜中分离的1,7-二苯基-4-庚烯-3-酮及其应用 | |
Yan et al. | Cytotoxic and pro-apoptotic effects of botanical drugs derived from the indigenous cultivated medicinal plant Paris polyphylla var. yunnanensis | |
CN115770249A (zh) | 治疗大肠癌的药物组合物及其用途 | |
CN113181166B (zh) | 莪术烯醇在制备抗肺癌药物中的应用 | |
WO2022095976A1 (zh) | 小分子sr9009在抗衰老以及减轻衰老引起的慢性炎症中的用途 | |
Wang et al. | Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1 | |
Song et al. | Arisaema heterophyllum Blume Monomer Stigmasterol Targets PPARγ and Inhibits the Viability and Tumorigenicity of Lung Adenocarcinoma Cells NCI‐H1975 | |
CN107260752B (zh) | 一种协同抗胰腺癌的药物组合物 | |
CN101870720A (zh) | 熊果酸的制备方法及其在治疗肿瘤疾病药物中的用途 | |
CN111514133A (zh) | 木香烃内酯和/或去氢木香内酯在制备治疗黑色素瘤的药品中的应用 | |
CN111150752A (zh) | 鸡骨草提取物在制备抗癌药物中的应用 | |
CN110664821A (zh) | 人参二醇在制备抑制pd-l1、肿瘤细胞增殖蛋白的表达的药物中的应用 | |
CN112439042B (zh) | 具有抑制肿瘤细胞活性和耐药性的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |